The latest price target for Blueprint Medicines (NASDAQ:BPMC) was reported by HC Wainwright & Co. on November 15, 2024. The analyst firm set a price target for $135.00 expecting BPMC to rise to within 12 months (a possible 52.22% upside). 41 analyst firms have reported ratings in the last year.

The latest analyst rating for Blueprint Medicines (NASDAQ:BPMC) was provided by HC Wainwright & Co., and Blueprint Medicines reiterated their buy rating.

The last upgrade for Blueprint Medicines Corp happened on May 6, 2024 when Leerink Partners raised their price target to $97. Leerink Partners previously had an underperform for Blueprint Medicines Corp.

The last downgrade for Blueprint Medicines Corp happened on June 5, 2023 when SVB Leerink changed their price target from $48 to $43 for Blueprint Medicines Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blueprint Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blueprint Medicines was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Blueprint Medicines (BPMC) rating was a reiterated with a price target of $135.00 to $135.00. The current price Blueprint Medicines (BPMC) is trading at is $88.69, which is out of the analyst’s predicted range.